

CURRICULUM VITAE

DATI PERSONALI

NOME: Angelina Anna Pirillo

DATA DI NASCITA: 26 Luglio 1967

LUOGO DI NASCITA: Saronno (VA)

RESIDENZA: Via Torino, 43 - LAZZATE (MB)

TELEFONO: 3397955938

STATO CIVILE: Coniugata

NAZIONALITA': Italiana

CURRICULUM STUDI

SCUOLA SUPERIORE: Maturità scientifica presso il Liceo Scientifico "Marie Curie" - Meda (MI).

Voto: 52/60

UNIVERSITA': Laurea in Scienze Biologiche (indirizzo Microbiologico) presso l'Università degli Studi di Milano conseguita il 09/05/1991. Voto: 110/110. Titolo della Tesi: "Metaboliti secondari da Baccharis".

ESPERIENZE DI LABORATORIO

- ✓ 1990/1991 Tesi Sperimentale svolta presso il Dipartimento di Chimica Organica ed Industriale dell'Università degli Studi di Milano, concernente l'estrazione, la separazione e l'identificazione di sostanze organiche naturali.
- ✓ Tirocinio pratico annuale per l'esercizio della professione di Biologo:
 - Primo semestre (Settembre 1991 - Marzo 1992) svolto presso il Dipartimento di Chimica Organica e Industriale dell'Università degli Studi di Milano. Ricerca riguardante l'estrazione, la separazione e l'identificazione di sostanze organiche naturali.
 - Secondo semestre (Marzo 1992 - Settembre 1992) svolto presso il Dipartimento di Fisiologia e Biochimica Generale - Sezione Biologica.
- ✓ 01/02/93 - 31/01/95: Corso di formazione della durata di due anni presso PHARMACIA, Centro Ricerche di Nerviano - Area Cardiovascolare. Titolo del progetto : "FORMAZIONE DI SPECIALISTI IN NUOVE METODOLOGIE PER L'INDAGINE E LO SVILUPPO DI FARMACI IPOLIPIDEMIZZANTI E ANTIATEROSCLEROTICI". Tale formazione è stata suddivisa in tre periodi:
 - 01/02/93 - 30/06/94: Studio sulla modificazione indotta dall'elastasi sulle HDL umane con indagine, in vitro, degli effetti di tali lipoproteine modificate sul metabolismo dei lipidi, presso Pharmacia, Laboratorio del Dr. G. Ghiselli.
 - 01/07/94 - 23/12/94: Studio riguardante LDL e Lp(a) umane e loro comportamento, in vitro (su macrofagi umani), dopo idrolisi enzimatica della componente fosfolipidica. Laboratorio del Dr. A. M. Scanu (Lipoprotein Study Unit, University of Chicago)
 - 06/02/95 - 17/02/95: Corso di formazione presso la sede di Tecnofarmaci, Pomezia, riguardante apprendimento di conoscenze in materia di programmazione, gestione strategica, valutazione ed organizzazione operativa dei progetti di ricerca applicata.

- ✓ 01/03/95-31/10/96: Studio riguardante ossidazione di lipoproteine a bassa densità e induzione di stress proteins in sistemi cellulari in vitro, Laboratorio del Prof. A.L. Catapano, Istituto di Scienze Farmacologiche, Università degli Studi, Milano.
- ✓ 01/11/96-31/10/99: Dottorato in Scienze Farmacognostiche, svolto presso il Laboratorio del Prof. A.L. Catapano, Istituto di Scienze Farmacologiche, Università degli Studi, Milano. Coordinatore del Dottorato: Prof. L. Puglisi. 04/02/2000 Conseguimento del titolo di Dottore di Ricerca con discussione di Tesi dal titolo: "Simvastatina e procianidine da Vitis vinifera: effetti sulla attività citotossica delle lipoproteine ossidate".
- ✓ 01/11/2000-31/10/2004: Titolare di un Assegno di Ricerca presso il Dipartimento di Scienze Farmacologiche-Milano, legato ad un progetto dal titolo "LIPOPROTEINE MODIFICATE ED ATEROSCLEROSI", riguardante la modificazione di varie classi lipoproteiche con diversi enzimi per valutare gli effetti su cellule della parete vascolare (colture primarie di cellule endoteliali e di monociti/macrofagi umani); valutazione dell'espressione di markers d'inflammation (molecole d'adesione, fattori chemotattici, metalloproteasi, citochine) e dei fattori di trascrizione coinvolti; valutazione dell'induzione della proliferazione cellulare.
- ✓ Dal 2004 al 2015: Titolare di Contratti di Lavoro a Progetto riguardanti le alterazioni delle funzioni biologiche delle HDL in seguito a modificazione enzimatica (Dipartimento di Scienze Farmacologiche-Milano; Ospedale E. Bassini, Cinisello Balsamo).
- ✓ Dal 2015: Elaborazione e stesura di pubblicazioni scientifiche; revisione manoscritti; elaborazione e stesura di progetti di ricerca.

PUBBLICAZIONI SCIENTIFICHE

1. Pirillo A, Catapano AL, Norata GD. Strategie di Silenziamento genico nel trattamento delle dislipidemie. *Giornale Italiano dell'Arteriosclerosi*. 2018;9(2):34-46.
2. Pirillo A, Catapano AL, Norata GD. Biological consequences of dysfunctional HDL. *Curr Med Chem*. 2018. doi: 10.2174/0929867325666180530110543.
3. Pirillo A, Catapano AL. PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle? *Eur Heart J*. 2018;39:2586-2588.
4. Pirillo A, Catapano AL. Proprotein Convertase Subtilisin Kexin 9 Inhibitors. *Cardiol Clin*. 2018 May;36(2):241-256.
5. Pirillo A, Bonacina F, Norata GD, Catapano AL. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. *Curr Atheroscler Rep*. 2018 Feb 14;20(3):12.
6. Faggiano P, Pirillo A, Griffo R, Ambrosetti M, Pedretti R, Scorcu G, Werren M, Febo O, Malfatto G, Favretto G, Sarullo F, Antonini-Canterin F, Zobbi G, Temporelli P, Catapano AL. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: the HEREDITY survey. *Int J Cardiol* 2018; 252:193-198.

7. Catapano AL, Pirillo A, Norata GD. Targeting cholesterol in non-ischemic heart failure: a role for LDLR gene therapy? *Mol Ther* 2017; 25(11):2435-2437 (IF 7.008)
8. Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S, Tarugi P, Catapano AL. Spectrum of mutation in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. *Atherosclerosis Suppl* 2017; 29:17-24 (IF 3.078)
9. Pirillo A, Norata GD, Catapano AL. Strategies for the use of non-statin therapies. *Curr Opin Lipidol* 2017; 28(6):458-464. (IF 3.853)
10. Catapano AL, Pirillo A, Norata GD. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. *Vasc Health Risk Manag* 2017; 13:343-351.
11. Casula M, Pirillo A, Norata GD, Catapano AL. PCSK9 inhibition in statin intolerant HeFH patients: what's new? *Eur J Prev Cardiol.* 2017; 24(14):1525-1527 (IF 4.542)
12. Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). *Atheroscler Suppl.* 2017 Jul;27:e1-e9. (IF 3.078)
13. Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low density lipoproteins: is cholesterol the link? A lesson from the clinical trials. *Br J Pharmacol* 2017 Nov; 174(22):3973-3985 (IF 6.81)
14. Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis.* 2017 May;27(5):396-406 (IF 3.318)
15. Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. *Cardiovasc Res.* 2016;112(1):429-442 (IF 5.878)
16. Pirillo A, Catapano AL, Norata GD. Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. *Curr Med Chem.* 2016;23(10):983-99 (IF 2016 3.249)
17. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. *Atherosclerosis* 2015; 243(2):449-461 (IF 3.942)
18. Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. *Trends Pharmacol Sci* 2015; 36(10):275-687 (IF 11.84)
19. Pirillo A, Catapano AL. Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events. *G Ital Cardiol (Rome)* 2015; 16(5):289-294
20. Pirillo A, Catapano AL. Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3. *Drug Des Dev Ther* 2015;9:2129-2137 (IF 2.881)

21. Pirillo A, Catapano AL. Statin intolerance: diagnosis and remedies. *Curr Cardiol Rep* 2015;17(5):582 (IF 1.83).
22. Pirillo A, Catapano AL, Norata GD. HDL in infectious disease and sepsis. *Handb Exp Pharmacol* 2015; 224:483-508.
23. Pirillo A, Catapano AL. Nutraceutica: definizione, regolamentazione e applicazioni. *GIFF* 2014;6(4):23-30.
24. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. *Cardiovasc Res* 2014 Aug 1;103(3):372-383. (IF 5.940)
25. Pirillo A, Tibolla G, Norata GD, Catapano AL. HDL: to treat or not to treat? *Curr Atheroscler Rep.* 2014 Aug;16(8):429. (IF 3.417)
26. Ammirati E, Bozzolo EP, Contri R, Baragetti A, Palini AG, Cianflone D, Banfi M, Uboldi P, Bottoni G, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, Norata GD. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. *Nutr Metab Cardiovasc Dis* 2014. (IF 3.323)
27. Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. *Curr Med Res Opin* 2014 (IF 2.653)
28. Cutuli L, Pirillo A, Uboldi P, Kuehn H, Catapano AL. 15-lipoxygenase-mediated modification of HDL3 impairs eNOS activation in human endothelial cells. *Lipids* 2014; 49(4):317-26. (IF 1.854)
29. Pirillo A, Catapano AL. Soluble lectin-like oxidized low density lipoprotein receptor-1 (sLOX-1) as a biochemical marker for atherosclerosis-related diseases. *Dis Markers* 2013; 35(5):413-418. (IF 2.174)
30. Pirillo A, Catapano AL. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. *Atheroscler Suppl.* 2013; 14(2):237-242. (IF 9.667)
31. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL and Atherosclerosis. *Mediators Inflamm* 2013; 2013:152786. (IF 2.417)
32. Pirillo A, Catapano AL, Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridemia. *Int J Cardiol.* 2013; 170(2 Suppl 1):S16-20. (IF 6.175)
33. Sala F, Cutuli L, Grigore L, Pirillo A, Chiesa G, Catapano AL, Norata GD Prevalence of classical CD14⁺⁺/CD16⁻ but not of intermediate CD14⁺⁺/CD16⁺ monocytes in hypoalphalipoproteinemia. *Int J Cardiol.* 2013; 168(3):2886-9. (IF 6.175)
34. Pirillo A, Norata GD, Catapano AL. Treating high density lipoprotein cholesterol (HDL-C):quantity versus quality. *Curr Pharm Des.* 2013;19(21):3841-57. (IF 3.288)
35. Pirillo A, Norata GD, Catapano AL. High-density lipoprotein subfractions: what the clinicians need to know. *Cardiology.* 2013;124(2):116-125. (IF 2.044)

36. Grigore L, Raselli S, Garlaschelli K, Redaelli L, Norata GD, Pirillo A, Catapano AL. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. *Eur J Clin Pharmacol* 2013;69(3):341-6. (IF 2.697)
37. Pirillo A, Uboldi P, Ferri N, Corsini A, Kuhn H, Catapano AL. Upregulation of Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (Lox-1) Expression in Human Endothelial Cells by Modified High Density Lipoproteins. *Biochem Biophys Res Commun.* 2012;428(2):230-3 (IF 2.406)
38. Predazzi IM, Norata GD, Vecchione L, Garlaschelli K, Amati F, Grigore L, Cutuli L, Pirillo A, Tramontana S, Romeo F, Novelli G, Catapano AL. Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. *PLoS One.* 2012;7(2):e31086. (IF 3.730)
39. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini AG, Norata GD. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. *J Am Heart Assoc.* 2012;1:27-41.
40. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. *Atherosclerosis* 2012; 220(2):381-386 (IF 3.706)
41. Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of High Density Lipoproteins as a player in the immune system. *Atherosclerosis.* 2012; 220(1):11-21 (IF 3.706)
42. Catapano AL, Grigore L, Pirillo A. The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders. *European Endocrinology,* 2011;7(2):92-5.
43. Norata GD, Pirillo A, Catapano AL. High density lipoproteins, immunity and atherosclerosis. *Curr Opin Lipidol.* 2011; 22(5):410-416. (IF 6.086)
44. Catapano AL, Norata GD, Pirillo A. Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches. *Curr Opin Lipidol.* 2011;22:324-325. (IF 6.086)
45. Banfi C, Brioschi M, Lento S, Pirillo A, Galli S, Cosentino S, Tremoli E, Mussoni L. Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro. *J Thromb Haemost.* 2011; 9(8):1608-19. (IF 5.731)
46. Pirillo A, Reduzzi A, Ferri N, Kuhn H, Corsini A, Catapano AL. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. *Atherosclerosis* 2011;214:331-337 (IF 3.794)
47. Pirillo A, Uboldi P, Catapano AL. Dual role of hypochlorite in the modification of high density lipoproteins. *Biochem Biophys Res Commun.* 2010;403:447-451 (IF 2.595)
48. Pirillo A, Uboldi P, Bolego C, Kuhn H, Catapano AL. The 15-lipoxygenase-modified High density lipoproteins 3 fail to inhibit the TNF α -induced inflammatory response in human endothelial cells. *J Immunol.* 2008;181:2821-2830. (IF 6.000).

49. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL. Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. *Arterioscler Thromb Vasc Biol.* 2008;28:925-931. (IF 6.858).
50. Pirillo A, Uboldi P, Pappalardo G, Kuhn H, Catapano AL. Modification of HDL₃ by mild oxidative stress increases ATP-binding cassette transporter-1-mediated cholesterol efflux. *Cardiovascular Research* 2007;75:566-574 (IF 6.127).
51. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL. Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. *Atherosclerosis.* 2007;191:265-271 (IF 4.287).
52. Norata GD, Pirillo A, Catapano AL. Modified HDL: Biological and physiopathological consequences. *Nutrition, Metabolism and Cardiovascular Diseases.* 2006;16:371-386 (IF 1.867).
53. Pirillo A, Uboldi P, Kuhn H, Catapano AL. 15-lipoxygenase-mediated modification of high density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. *BBA- Mol. Cell Biol. Lipids* 2006;1761:292-300. (IF 3.117).
54. Pellegatta F, Bragheri M, Grigore L, Raselli S, Maggi FM, Brambilla C, Reduzzi A, Pirillo A, Norata GD, Catapano AL. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. *Int J Mol Med.* 2006;17:203-208. (IF 2.090)
55. Banfi C, Brioschi M, Wait R, Begum S, Gianazza E, Pirillo A, Mussoni L, Tremoli E. Proteome of endothelial cell-derived procoagulant microparticles *Proteomics.* 2005;5:4443-4455. (IF 6.088).
56. Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, Eriksson P. Oxidised-HDL₃ induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. *Br J Haematol.* 2004;127:97-104. (IF 3.195)
57. Norata GD, Pirillo A, Pellegatta F, Inoue H, Catapano AL. Native LDL and oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-kappaB, CRE dependent pathway and affect PGE₂ synthesis. *Int J Mol Med.* 2004;14:353-359. (IF 3.190)
58. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. *Cardiovasc Res.* 2003;59:169-180. (IF 5.164)
59. Norata GD, Pirillo A, Catapano AL. Statins and oxidative stress during atherogenesis. *J Cardiovasc Risk.* 2003;10:181-189. (IF 1.99)
60. Catapano AL, Norata GD, Pirillo A. Lipoproteine ossidate ed endotelio. *Giornale della Arteriosclerosi.* 2002;27:53-57.

61. Eberini I, Calabresi L, Wait R, Tedeschi G, Pirillo A, Puglisi L, Sirtori CR, Gianazza E. Macrophage metalloproteinases degrade high-density-lipoprotein-associated A-I at both N- and C-termini: *Biochemical Journal*. 2002;362:627-634. (IF 4.326)
62. Pirillo A, Norata GD, Zanelli T, Catapano AL. Overexpression of hsp70i in Cos-1 cells fails to protect from OxLDL cytotoxicity. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2001;21: 348-354. (IF 5.816)
63. Pirillo A, Ghiselli G. Elastase-mediated modification of high density lipoproteins leads to increased uptake by macrophages via the class B type I scavenger receptor. *Biochemical and Biophysical Research Communications*. 2000; 271(2): 386-391. (IF 3.055)
64. Pirillo A, Zhu W, Norata GD, Zanelli T, Barberi L, Roma P, Catapano AL. Oxidized lipoproteins and endothelium. *Clinical Chemistry and Laboratory Medicine*. 2000; 38(2): 155-160. (IF 1.744)
65. Pirillo A, Zhu W, Roma P, Rasetti MF, Caruso D, Pellegatta F, Catapano AL. Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells. *FEBS Letters* 1999; 462: 113-116. (IF 3.72)
66. Pirillo A, Jacoviello C, Longoni C, Radaelli A, Catapano AL. Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial and smooth muscle cells. *Biochemical and Biophysical Research Communications*. 1997; 231:437-441. (IF 2.671)
67. Roma P, Pirillo A, Zhu WM, Catapano AL. Oxidized LDL trigger the expression of hsp70 in cultured endothelial cells, in AM Gotto JR., R. Paoletti, LC Smith, AL Catapano, AS Jackson, *Drugs affecting lipid metabolism*, 1996, 603-612.
68. Zhu WM, Roma P, Pirillo A, Pellegatta F, Catapano AL. Human endothelial cells exposed to oxidized LDL express hsp70 only when proliferating. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 1996; 16:1104-1111. (IF 4.962)
69. Musanti R, Giorgini L, Lovisolo P, Pirillo A, Chiari A, Ghiselli G. Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. *Journal of Lipid Research*, 1996; 37:1-14. (IF 3.62)
70. Zhu WM, Roma P, Pirillo A, Pellegatta F, Catapano AL. Oxidized LDL induce hsp70 expression in human smooth muscle cells. *FEBS Letters*, 1995; 372 1-5. (IF 3.842)
71. Fogliatto G, Musanti R, Pirillo A, Ghiselli G. Oxidized lipoproteins induce a long lasting inhibition of nitric oxide synthase from a murine endothelioma cell line (bEnd.4). *J Cardiovascular Risk*, 1995; 2: 123-130.
72. Pirillo A, Verotta L, Gariboldi P, Torregiani E, Bombardelli E. Constituents of Nothapodytes-Foetida. *Journal of the Chemical Society. Perkin Transactions I*. 1995;5: 583-587. (IF 1.641)

73. Abdallah RM, Ghazy NM, Assad A, El-Sebakhy NA, Pirillo A, Verotta L. Constituents of the Egyptian *Astragalus tomentosus* Lam. *Pharmazie*, 1994; 49: 377-378. (IF 0.334)
74. Abdallah RM, Ghazy NM, El-Sebakhy NA, Pirillo A, Verotta L. Astragalosides from Egyptian *Astragalus spinosus* Vahl. *Pharmazie*, 1993; 48: 452-454. (IF 0.34)

CAPITOLI DI LIBRI

1. Pirillo A., and Catapano A.L. (2018) Familial Hypercholesterolemia. In: Vasan, R., Sawyer, D., The Encyclopedia of Cardiovascular Research and Medicine. vol. 2, p. 285-297. Oxford: Elsevier.
2. Pirillo, A., Norata, G. D., Catapano, A. L. (2017) Advances in Hypercholesterolemia. In: Samuel Chackalamannil, David P Rotella and Simon E Ward, (eds.) Comprehensive Medicinal Chemistry III vol. 7, pp. 663-693. Oxford: Elsevier. <http://dx.doi.org/10.1016/B978-0-12-409547-2.12435-7>. ISBN: 9780128032008
3. Angela Pirillo, Alberico L. Catapano, (2015), STATINS AND LOMITAPIDE: A SUITABLE RESPONSE FOR HoFH?, in Combination Therapy in Dyslipidemia, Banach M. editor, 1st ed. Springer International Publishing Switzerland 2015. DOI 10.1007/978-3-319-20433-8_8
4. Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano, (2012), PREVENTION AND CARE OF ATHEROSCLEROSIS, in *Pharmacology*, [Eds. UNESCO-EOLSS Joint Committee], in *Encyclopedia of Life Support Systems (EOLSS)*, Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford ,UK, [<http://www.eolss.net>]
5. Angela Pirillo, Giuseppe Danilo Norata, Alberico Luigi Catapano, (2014), PRODUCTION AND METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS IN BOTH THE NORMAL AND DIABETIC STATES, in Lipoprotein in Diabetes Mellitus, Jenkins, Alicia J.; Toth, Peter P.; Lyons, Timothy J. (Eds.), Humana Press